Nurix TherapeuticsÂ Inc (NRIX) Peer Comparison

$26.41

$-0.47 (-1.75%)

As on 28-Aug-2026 13:40EDT

Market cap

$2,773 Mln

Revenue (TTM)

$37 Mln

P/E Ratio

--

P/B Ratio

6.9

Div. Yield

0 %

Edit

	Nurix TherapeuticsÂ Inc (NRIX)	Biovie Inc (BIVI)	Bio-Techne Corp (TECH)
Market cap ($ Mln)	2,773	16	11,268
Revenue ($ Mln)	37	--	1,215
Net Profit ($ Mln)	-341.35	-22.07	181.86
Net Margin (%)	-928.44	--	14.97
RoE (%)	-72.52	0.00	9.03
Price to Earnings	--	--	62.34
Price-To-Book	6.88	1.53	5.34

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Nurix TherapeuticsÂ Inc (NRIX)	Biovie Inc (BIVI)	Bio-Techne Corp (TECH)
Operating Revenue	83.98	0.00	1,215.04
Cost of Revenue	18.86	0.18	415.97
Gross Profit	65.12	-0.23	790.27
Operating Expenses	350.79	22.48	547.18
Operating Profit (EBIT)	-285.67	-22.65	251.89
Other Income	--	0.00	0.00
Profit before Tax	-263.70	-22.07	240.68
Provision for Tax	0.76	0.00	58.82
Profit after Tax (Net Income)	-264.46	-22.07	181.86
Minority Interest	--	0.00	0.00
Consolidated Profit	--	0.00	0.00

Liabilities ($ Mln)

	Nurix TherapeuticsÂ Inc (NRIX)	Biovie Inc (BIVI)	Bio-Techne Corp (TECH)
Shareholder's Funds	538.75	10.27	2,108.22
Minority Interest	--	0.00	0.00
Non-Current Liabilities	62.92	0.18	314.81
Current Liabilities	86.47	3.80	163.70
Total Liabilities	688.14	21.56	2,557.87

Assets ($ Mln)

	Nurix TherapeuticsÂ Inc (NRIX)	Biovie Inc (BIVI)	Bio-Techne Corp (TECH)
Non-Current Assets	81.32	0.61	1,842.33
Current Assets	606.82	13.64	744.40
Total Assets	688.14	21.56	2,557.87
Total Debt*	55.73	0.28	274.15
Net Current Assets	520.35	0.00	0.00

Cashflow ($ Mln)

	Nurix TherapeuticsÂ Inc (NRIX)	Biovie Inc (BIVI)	Bio-Techne Corp (TECH)
Cash From Operating Activities	-249.47	-19.03	287.56
Cash Flow from Investing Activities	147.85	--	-35.18
Cash from Financing Activities	238.64	12.73	-253.91
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Nurix TherapeuticsÂ Inc (NRIX)	Biovie Inc (BIVI)	Bio-Techne Corp (TECH)
ROCE (%)	-46.00	-85.61	3.03
ROE (%)	-49.63	-149.47	8.83
ROA (%)	-38.96	-85.34	6.00
EBIT Margin (%)	--	--	20.25
Net Margin (%)	-314.90	--	14.97
Cash Profit Margin (%)	--	--	0.00

Growth Ratios

	Nurix TherapeuticsÂ Inc (NRIX)	Biovie Inc (BIVI)	Bio-Techne Corp (TECH)
Revenue Growth (%)	0.54	--	-0.38
EBIT Growth (%)	--	-28.86	130.05
Net Profit Growth (%)	-36.62	-25.83	147.77
EPS Growth (%)	--	75.00	155.17
Book Value Growth (%)	--	5.81	9.00

Valuation Ratios

	Nurix TherapeuticsÂ Inc (NRIX)	Biovie Inc (BIVI)	Bio-Techne Corp (TECH)
Price / Earnings	--	-0.78	109.18
Price / Book Value	--	0.72	4.18
Dividend Yield (%)	--	--	--
EV/EBITDA	2.19	0.21	38.25
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Nurix TherapeuticsÂ Inc (NRIX)	Biovie Inc (BIVI)	Bio-Techne Corp (TECH)
Debt to Equity	0.10	0.00	0.00
Short term debt to equity ratio	0.01	0.01	0.00
Current Ratio	7.02	3.59	4.55
Quick Ratio	--	3.59	3.35
Interest Coverage	--	-1,232.05	45.53

Operating Efficiency Ratios

	Nurix TherapeuticsÂ Inc (NRIX)	Biovie Inc (BIVI)	Bio-Techne Corp (TECH)
Debtors to sales (%)	2.75	--	17.83
Asset Turnover	0.12	0.00	0.40
Receivable days	6.52	--	67.12
Inventory Days	--	--	157.03
Payable days	219.83	4,607.67	26.92
Cash Conversion Cycle	--	--	197.23

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly